SBIR AND STTR FUNDING
OPPORTUNITIES
OPPORTUNITIES
Non-dilutive funding for early-stage research and development.
[Omnibus Solicitations] [Specific Opportunities]
SBIR and STTR grant funding opportunities offer small business entrepreneurs a chance to obtain non-dilutive funding for early-stage research and development. Applications are accepted three times a year.
NIH advertises the availability of grant support through notices of funding opportunities (NOFOs), previously referred to as funding opportunity announcements (FOAs).
Helpful Tips
- Follow these step-by-step instructions to learn how to apply for these funding opportunities, including resources on how to prepare your application.
- Read Program Descriptions and Research Topics.
- Refer to SBA approved waiver eligible topics.
Omnibus Solicitations (Parent Announcements)
Researcher-initiated ideas are proposed via the SBIR and STTR Omnibus grant solicitations. These funding opportunities do not specify a topic, though they link to identified topics of interest for each participating awarding component. Most small business applications to NIH are submitted to the Omnibus solicitations.
Read the Program Descriptions and Research Topics to understand the awarding components, their topics of interest, and staff contacts. For topics that require additional funding to reach the marketplace, please refer to our list of SBA approved waiver eligible topics.
Standard Application Due Dates: September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays move to the next business day.
Notice of Information: Anticipated Publication of the PHS 2023-2 Omnibus Solicitations
We anticipate publishing the PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications in the summer of 2023. The expected first application due date will be September 5, 2023.
These notices of funding opportunities (NOFOs) will be a re-issuance of the following omnibus solicitations:
- PA-22-176: PHS 2022-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- PA-22-177: PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
- PA-22-178: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- PA-22-179: PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
Please refer to the notice (NOT-OD-23-124) for more information.
Specific Funding Opportunities
Some SBIR/STTR grant solicitations are focused on specific research areas. Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program.
| Title | NOFO/Notice Number | Organization | Release Date | Due Date(s) | Expiration Date | Clinical Trials |
|---|---|---|---|---|---|---|
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) | PAS-22-197 | NIANINDS | 06/21/2022 | 09/06/2025 | Optional | |
| Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) | PAS-22-196 | NIANINDS | 06/21/2022 | 09/06/2025 | Optional | |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-21-057 | NINDS | 11/19/2020 | February 22, 2021, June 22, 2021, February 22, 202...(see announcement for full details) | 09/08/2023 | Optional |
| Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) | RFA-TR-22-029 | NCATS | 07/13/2022 | 07/13/2023 | Required | |
| Blueprint Medtech: Small Business Translator (U44 - Clinical Trial Optional) | PAR-21-282 | NIDANIMHNEINIDCRNIAOBSSRNCCIHNIBIBNICHDNIAAANINDS | 08/20/2021 | October 20, 2021; February 18, 2022; June 20, 2022...(see announcement for full details) | 06/21/2024 | Optional |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) | PAR-21-233 | NINDSNIAAANIANCCIHNICHDNIBIBNIMHOBSSRNIDCRNIDANEI | 04/23/2021 | August 10, 2021, February 9, 2022, August 9, 2022,...(see announcement for full details) | 04/06/2024 | Optional |
| Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (U43/U44 - Clinical Trail Not Allowed) | RFA-TR-22-032 | NCATSNINDS | 09/19/2022 | Multiple dates, see announcement....(see announcement for full details) | 08/22/2023 | Not Allowed |
| Botulinum Toxin Potency Assay using Tissue Chips (BoT PATCh) (UT1, UT2 Clinical Trail Not Allowed) | RFA-TR-22-031 | NCATSNINDS | 09/19/2022 | Multiple dates, see announcement....(see announcement for full details) | 08/22/2023 | Not Allowed |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) | PAR-21-059 | NINDS | 11/19/2020 | March 15, 2021, June 22, 2021, February 22, 2022, ...(see announcement for full details) | 09/08/2023 | Optional |
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional) | RFA-DA-24-038 | NIDA | 04/18/2023 | 02/15/2025 | Optional | |
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) | RFA-DA-23-021 | NIDA | 03/28/2022 | Multiple dates, see announcement....(see announcement for full details) | 02/15/2025 | Optional |
| Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R41/R42 Clinical Trial Optional) | RFA-DA-24-017 | NIDA | 05/23/2023 | 11/10/2023 | Optional | |
| Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) | RFA-DA-24-018 | NIDA | 05/23/2023 | 11/11/2023 | Optional | |
| HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed) | PAR-23-069 | NINDSNCATSNCCIHNEINIAMS | 01/03/2023 | 09/06/2025 | Not Allowed | |
| HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed) | RFA-NS-23-007 | NINDSNCATSNCCIHNCINHLBINIANIAAANIAMSNICHDNIGMSNIMHORIP | 09/15/2022 | Multiple dates, see announcement....(see announcement for full details) | 04/05/2025 | Not Allowed |
| HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) | RFA-NS-23-006 | NINDSNCATSNCCIHNHLBINIANIAAANIAMSNICHDNIGMSNIMHORIP | 09/15/2022 | Multiple dates, see announcement....(see announcement for full details) | 04/05/2025 | Not Allowed |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed) | PAR-23-267 | NCATS | 04/18/2023 | Multiple dates, see announcement....(see announcement for full details) | 06/07/2025 | Not Allowed |
| Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed | PAR-23-268 | NCATS | 04/18/2023 | 06/07/2025 | Not Allowed | |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) | RFA-MD-23-003 | NIMHDNCATSNHLBINIANIAAANIBIBNIDCRNIDDKNINDS | 01/30/2023 | 09/07/2023 | Optional | |
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) | PAR-22-102 | NIAAA | 01/21/2022 | Multiple dates, see announcement....(see announcement for full details) | 12/05/2024 | Optional |
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) | PAR-22-103 | NIAAA | 01/21/2022 | Multiple dates, see announcement....(see announcement for full details) | 12/05/2024 | Optional |
| Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) | PAR-23-032 | NIAMS | 10/26/2022 | 09/06/2025 | Not Allowed | |
| Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed) | PAR-21-298 | NICHDNIMH | 08/31/2021 | Only accepting applications for the AIDS Applicati...(see announcement for full details) | 12/10/2023 | Not Allowed |
| Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed) | PAR-21-297 | NICHDNIAIDNIMH | 08/31/2021 | Only accepting applications for the AIDS Applicati...(see announcement for full details) | 12/10/2023 | Not Allowed |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) | PAR-21-224 | NINDS | 05/05/2021 | Standard dates apply *** Note new SBIR/STTR Standa...(see announcement for full details) | 04/06/2024 | Optional |
| NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-23-009 | NHLBI | 11/16/2021 | 02/29/2024 | Optional | |
| NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | RFA-HL-23-008 | NHLBINCATS | 11/16/2021 | 02/29/2024 | Optional | |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) | PAR-21-082 | NIAID | 01/14/2021 | May 14, 2021; September 13, 2021; January 14, 2022...(see announcement for full details) | 01/14/2024 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required) | PAR-21-267 | NINDS | 07/16/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 04/06/2024 | Required |
| NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) | PAR-21-266 | NINDS | 07/15/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 04/06/2024 | Required |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) | PAR-21-265 | NINDS | 07/15/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 04/06/2024 | Optional |
| NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) | PAR-21-114 | NINDS | 01/25/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 01/06/2024 | Not Allowed |
| Notice of Special Interest (NOSI) of NIDCR in Supporting Dental, Oral, and Craniofacial Research Using Bioinformatic, Computational, and Data Science Approaches | NOT-DE-20-006 | NIDCR | 06/05/2020 | 08/08/2023 | Not Allowed | |
| Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research | NOT-AI-22-004 | NIAIDNIAMSNCCIHNCI | 11/23/2021 | 01/08/2025 | Optional | |
| Notice of Special Interest (NOSI): Advancing NEI AGI Research on newly Identified Factors Into Models of Visual System Regeneration | NOT-EY-22-002 | NEI | 01/10/2022 | 02/10/2025 | Optional | |
| Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies | NOT-AI-21-056 | NIAIDNIDA | 06/17/2021 | 05/08/2024 | Not Allowed | |
| Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease | NOT-HG-22-007 | NHGRI | 12/09/2021 | 11/05/2024 | Not Allowed | |
| Notice of Special Interest (NOSI): Addressing Accessibility Inequities with COVID Home-Based Testing for Individuals with Visual Impairment | NOT-EY-22-010 | NEI | 02/04/2022 | 03/09/2024 | Optional | |
| Notice of Special Interest (NOSI): Advancing Development of Rapid Point-of-Care Hepatitis C Virus Diagnostics | NOT-AI-23-001 | NIAIDNCINIBIB | 11/23/2022 | 01/08/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application | NOT-HG-21-018 | NHGRI | 12/04/2020 | 01/10/2024 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) | NOT-DE-21-012 | NIDCR | 09/01/2021 | 09/05/2025 | Not Allowed | |
| Notice of Special Interest (NOSI): Advancing Innovative Non-invasive Physiologic Monitoring To Improve Fetal Assessment | NOT-HD-21-053 | NICHD | 12/28/2021 | 05/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research for Amyotrophic Lateral Sclerosis (ALS) | NOT-NS-23-062 | NINDS | 02/06/2023 | 06/24/2023 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs) | NOT-AI-23-013 | NIAIDNIAMSNIMHNINDS | 11/25/2022 | 01/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-007 | NIAID | 11/25/2022 | 01/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-031 | NIAID | 02/23/2023 | 01/15/2026 | Optional | |
| Notice of Special Interest (NOSI): BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech | NOT-NS-22-052 | NINDSNIAAANIBIBNCCIHNEINIANICHDOBSSRNIDCDNIDANIMH | 01/05/2022 | 06/21/2024 | Optional | |
| Notice of Special Interest (NOSI): Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (SBIR/STTR) | NOT-AT-21-001 | NCCIH | 10/23/2020 | 01/05/2024 | Optional | |
| Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) | NOT-HL-23-066 | NHLBI | 01/31/2023 | 09/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Development of Innovative Informatics and Data Science Technologies, Tools, and Methods for Vision Research | NOT-EY-23-005 | NEI | 04/03/2023 | 02/16/2026 | Not Allowed | |
| Notice of Special Interest (NOSI): Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults | NOT-MH-23-250 | NIMH | 05/19/2023 | 09/08/2026 | Optional | |
| Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College | NOT-AA-22-001 | NIAAA | 12/09/2021 | 09/09/2025 | Optional | |
| Notice of Special Interest (NOSI): Genomics Education Interactive Digital Media Resources (SBIR/STTR) | NOT-HG-21-038 | NHGRI | 08/26/2021 | 12/31/2024 | Not Allowed | |
| Notice of Special Interest (NOSI): HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech | NOT-NS-23-002 | NINDSNCCIHNCINEINIANIAAANIAMSNICHDNIDANIDCRNIMH | 08/03/2022 | 06/21/2024 | Optional | |
| Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability | NOT-DC-21-001 | NIDCD | 02/16/2021 | 01/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health | NOT-OD-21-100 | OBSSRNIMHDNIDANIMHORWHNIDCDSGMROODPNIANHLBINCININRNCCIHNEINICHD | 04/08/2021 | 06/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Methods Development in Natural Products Research (SBIR/STTR) | NOT-AT-20-015 | NCCIH | 07/16/2020 | 09/06/2023 | Not Allowed | |
| Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings | NOT-CA-21-062 | NCI | 07/23/2021 | 09/07/2024 | Optional | |
| Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition | NOT-HD-21-027 | NICHDNIAAANCINIMHNIAMSOBSSRNIBIBNIDCR | 06/22/2021 | 01/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Optimization of Data Storage and Utilization for the Sequence Read Archive (SRA) | NOT-GM-23-015 | NIGMSNLMODSS | 12/14/2022 | 12/19/2025 | Optional | |
| Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services | NOT-MH-22-110 | NIMHNIDAORWH | 02/08/2022 | 05/08/2025 | Optional | |
| Notice of Special Interest (NOSI): Promoting Language and Communication in Minimally Verbal/Non-Speaking Individuals with Autism | NOT-DC-23-009 | NIDCD | 04/03/2023 | 06/06/2026 | Optional | |
| Notice of Special Interest (NOSI): Research Addressing Eye and Vision Health Equity/Health Disparities | NOT-EY-22-004 | NEINIMHD | 02/14/2022 | 01/25/2025 | Optional | |
| Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings | NOT-MH-21-230 | NIMHNIDA | 04/16/2021 | 09/08/2023 | Optional | |
| Notice of Special Interest (NOSI): Small Business Digital Technologies for Early Detection, Characterization and Monitoring of Senescence-Related Changes | NOT-AG-23-004 | NIA | 02/07/2023 | 01/06/2026 | Optional | |
| Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications. | NOT-EB-23-002 | NIBIBNCCIHNCINHLBINIANIAIDNICHDNIGMS | 04/14/2023 | 05/17/2026 | Optional | |
| Notice of Special Interest (NOSI): Technological Innovations for Advancing Clinical SPECT Imaging | NOT-EB-22-006 | NIBIB | 03/21/2022 | 05/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection | NOT-AI-22-043 | NIAID | 04/29/2022 | 05/08/2025 | Not Allowed | |
| Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace | NOT-MH-21-125 | NIMHNIANIAAANIBIBNINDSNIDANEINCCIHNICHDNIDCD | 03/03/2021 | 01/06/2024 | Not Allowed | |
| Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes | NOT-CA-21-031 | NCINIA | 01/27/2021 | 01/08/2024 | Optional | |
| Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | NOT-CA-23-004 | NCI | 10/17/2022 | 07/02/2025 | Optional | |
| Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research | NOT-CA-22-037 | NCINHLBINIANIDANIMHNINROBSSR | 01/27/2022 | 03/09/2024 | Optional | |
| Notice of Special Interest: Biomarker Discover and Validation in Functional Neurological Disorders | NOT-NS-22-010 | NINDS | 10/01/2021 | 01/08/2025 | Optional | |
| Notice of Special Interest: Development and Implementation of Clinical Informatics Tools to Enhance Patients Use of Genomic Information | NOT-HG-22-011 | NHGRI | 01/06/2022 | 12/31/2025 | Optional | |
| Notice of Special Interest: Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) | NOT-AG-22-032 | NIA | 09/28/2022 | 09/05/2025 | Optional | |
| Notice of Special Interest: Kidney Precision Medicine Technology Development and Translation | NOT-DK-21-007 | NIDDK | 12/02/2020 | 09/06/2023 | Optional | |
| Notice of Special Interest: NIDCD Health Disparities and Inequities Research | NOT-DC-21-003 | NIDCDSGMRO | 06/11/2021 | 05/08/2024 | Optional | |
| Notice of Special Interest: NIGMS Priorities for Small Business Development of Sepsis Diagnostics and Therapeutics | NOT-GM-20-028 | NIGMS | 06/02/2020 | 09/12/2023 | Optional | |
| Notice of Special Interest: Research on Pain, Pain Management, and Opioids in Aging | NOT-AG-22-004 | NIA | 12/22/2021 | 01/08/2025 | Optional | |
| Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) | NOT-NS-22-017 | NINDSNIDCRNEINCINIA | 11/12/2021 | 01/08/2025 | Not Allowed | |
| Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) | RFA-ES-23-008 | NIEHS | 03/21/2023 | 07/08/2023 | Not Allowed | |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) | PAR-21-226 | ORIP | 04/30/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 09/06/2024 | Not Allowed |
| Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) | PAR-21-225 | ORIP | 04/30/2021 | Standard dates apply The first standard due date f...(see announcement for full details) | 09/06/2024 | Not Allowed |
| SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed) | RFA-ES-23-005 | NIEHS | 03/06/2023 | July 14, 2023...(see announcement for full details) | 07/15/2023 | Not Allowed |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) | RFA-CA-23-034 | NCI | 04/21/2023 | Not Applicable...(see announcement for full details) | 08/22/2023 | Optional |
| Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) | RFA-CA-23-035 | NCINHGRINIBIBNIDA | 04/21/2023 | August 21, 2023...(see announcement for full details) | 08/22/2023 | Not Allowed |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) | RFA-MD-23-002 | NIMHDNCATSNIDCRNINDS | 01/30/2023 | 09/07/2023 | Optional | |
| Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial not allowed) | PAR-21-247 | NHGRINIAIDNCI | 07/12/2021 | October 1, 2021; June 15, 2022; June 15, 2023 All...(see announcement for full details) | 06/16/2023 | Not Allowed |
